DETAILS
Description:
The febuxostat tablet is an anti-gout drug. Febuxostat has a significant inhibitory effect on both oxidized and reduced XOR, and therefore its effect of lowering uric acid is stronger and longer lasting, so this product can be used to treat chronic hyperuricemia of gout.
| Product Name | Febuxostat |
| Part Used | Febuxostat |
| Appearance | White Powder |
| Active Ingredient | Febuxostat |
| Specification | 99% |
Application:
Febuxostat (INN; trade names Adenuric [EU], Febutaz [India] and Uloric [US]) is a urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and chronic gout.
Febuxostat reduces the production of uric acid in your body. Uric acid buildup can lead to gout or kidney stones.
Febuxostat is used to treat gout.
Febuxosta ,is a anti-gout Pharmaceutical Raw Materials.
Certificate of Analysis
| Batch Number | Z20190412001 | ||
| Production Date | 2019.04.12 | ||
| Batch Quantity | 80 KGS | ||
| Item | Test Standard | Testing Result | |
| Appearance | Powder | Complies | |
| Color | White fine Powder | Complies | |
| Particle Size | 100% pass 80 mesh | Complies | |
| Oder | Characteristic | Complies | |
| Taste | Characteristic | Complies | |
| Loss on Drying | ≤5.0% | 2.20% | |
| Residue on Ignition | ≤0.1% | 0.05% | |
| Residual acetone | ≤0.1% | Complies | |
| Residual Ethanol | ≤0.5% | Complies | |
| Heave Mentals | ≤10ppm | Complies | |
| Na | ≤0.1% | <0.1% | |
| Pb | ≤3 ppm | Complies | |
| Total Plate | <1000CFU/g | Complies | |
| Yeast & Mold | <100 CFU /g | Complies | |
| E. Coli | Negative | Complies | |
| Salmonella | Negative | Complies | |
| Conclusion: Conform with USP Standard | |||
Storage:Closed container. dry & cool. keep away from moisture &strong light
Shelf life:24 Months
